UT Southwestern Considers Genetix Specialty Drug Contract
- Document date
- Nov 14, 2026
The 30-second brief
The University of Texas Southwestern Medical Center will consider a contract with Genetix Biotherapeutics Inc. for specialty cancer and oncology pharmacy drugs used to treat sickle cell-related diseases.
Genetix Biotherapeutics Inc holds this supplies contract with The University of Texas System | State of Texas.
Hear about the next contract at The University of Texas System | State of Texas early.
Get pre-RFP alerts freeFree account · 30-second setup · No credit card
Contract details
- Contract type
- Supplies
- Document date
- November 14, 2026
- Source document
- The University of Texas System Agenda Board of Meeting 2026-11-18 (Agenda)
Genetix Biotherapeutics Inc's other public contracts
More The University of Texas System | State of Texas contracts
Questions about this contract
Who was awarded the supplies contract by The University of Texas System | State of Texas?
Genetix Biotherapeutics Inc was awarded this supplies contract by The University of Texas System | State of Texas, as recorded on November 14, 2026.
What type of contract is this?
This is a Supplies contract, documented as a agenda record.
Where was this contract approved?
This contract appears in The University of Texas System Agenda Board of Meeting 2026-11-18 (Agenda), dated November 14, 2026 from The University of Texas System | State of Texas. Civic IQ extracts contract records directly from agency meeting documents and solicitations.
What other contracts does Genetix Biotherapeutics Inc hold?
Genetix Biotherapeutics Inc may hold additional government contracts. View their full contract history, the agencies they serve, and total tracked spend on their Civic IQ vendor profile.
Show 1 more question
What is The University of Texas System | State of Texas currently buying?
Explore The University of Texas System | State of Texas's vendors, signed contracts, and active RFPs on their Civic IQ agency profile.